Bradley G. Somer, MD, associate professor, Department of Hematology and Medical Oncology, University of Tennessee Health Science Center, medical oncologist, senior partner, Executive Cancer Council, and head of strategic expansion/development, West Cancer Center Research Program, West Cancer Center, discusses the importance of taking a proactive approach towards the use of biosimilars in oncology.

A number of biosimilars are poised to enter the marketplace, explains Somer. As such, Somer advises that practices form a small committee to aimed at optimizing biosimilars once they become available.  

This group could include oncology pharmacists, quality committee individuals, as well as other investigators within the practice, concludes Somer.

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Biosimilars

 Biosimilars condition center page is a comprehensive resource for clinical news and expert insights on currently available and investigational biosimilars for reference drugs such as trastuzumab, rituximab, bevacizumab, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates with biosimilars and ongoing research with these types of agents.

University of Tennessee West Cancer Center

Cancer Centers

Partner

Bradley G. Somer, MD, discusses the importance of taking a proactive approach towards the use of biosimilars in oncology.
 

Dr. Somer on the Expansion of Biosimilars in Oncology